Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound

A kind of quinoline, compound technology, is applied in quinoline compound, its preparation, the pharmaceutical composition containing this compound and the application field of this compound, can solve the problems such as limited structure

Inactive Publication Date: 2011-03-30
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many inhibitors developed for this signaling pathway, the structure is still very limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
  • Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
  • Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0164] Preparation Example 1 Preparation of intermediate [3-(4-methylpiperazin-1-yl)-7-trifluoromethyl-5-hydroxyquinoline]

[0165]

[0166] Preparation of 7-trifluoromethyl-5-nitroquinoline: 3-nitro 5-aminobenzotrifluoride (7.5g), glycerol (12.3g), and arsenic pentoxide (6.8g) were added to the reaction flask After stirring until the mixture is uniform, slowly add concentrated sulfuric acid (8g), first react at 130°C for one hour, then raise the temperature to 180°C for four hours. After the reaction is completed, the reaction solution is cooled to room temperature, and then adjusted to be alkaline with 4mol / L sodium hydroxide solution, the solid is filtered out, the solid is dissolved in ethanol, decolorized by activated carbon, the solvent is evaporated, and 7- Trifluoromethyl-5-nitroquinoline (1.7 g, 15%). 1 H-NMR (300MHz, CDCl 3 ): δ9.14(dd, 1H, J1=1.5Hz, J2=4.2Hz), 9.03(d, 1H, J=9.0Hz), 8.71(s, 1H), 8.54(d, 1H, J=1.5Hz ), 7.77 (dd, 1H, J1=9.0Hz, J2=4.2Hz).

[0167...

preparation Embodiment 2

[0171] Preparation Example 2 Preparation of Compound IA-1:

[0172] The compound 3-(4-methylpiperazin-1-yl)-7-trifluoromethyl-5-hydroxyquinoline (16.0mg, 0.05mmol) was dissolved in THF (1ml), and Cs was added under ice-cooling 2 CO 3 (25.0mg, 0.078mmol), after stirring for 10min, m-nitrobenzyl bromide (11.6mg, 0.054mmol) was added to the reaction solution under nitrogen protection, the temperature was slowly raised to room temperature, stirred for two hours, concentrated and separated by column chromatography The target compound IA-1 (20.0 mg, 0.045 mmol) was purified with a yield of 90%.

[0173]

[0174] IA-1: 1 H-NMR (300MHz, CDCl 3 ): δ8.87(d, 1H, J=2.7Hz), 8.47(s, 1H), 8.25(d, 1H, J=9.3Hz), 7.93(s, 1H), 7.81(d, 1H, J= 7.5Hz), 7.73(d, 1H, J=2.4Hz), 7.63(t, 1H, J1=7.8Hz, J2=8.1Hz), 6.98(s, 1H), 5.37(s, 2H), 3.41(t , 4H, J1=4.8Hz, J2=5.1Hz), 2.64(t, 4H, J1=5.1Hz, J2=4.8Hz), 2.38(s, 3H).

preparation Embodiment 3

[0175] Preparation Example 3 Preparation of Compound IA-2:

[0176] Preparation of intermediate 3-(4-methylpiperazin-1-yl)-5-hydroxyquinoline:

[0177]

[0178] In addition to using 5-nitroquinoline instead of 7-trifluoromethyl-5-nitroquinoline, using the same method as in Preparation Example 1 to synthesize 3-(4-methylpiperazin-1-yl)-7- The same steps as trifluoromethyl-5-hydroxyquinoline synthesized 3-(4-methylpiperazin-1-yl)-5-hydroxyquinoline.

[0179] Preparation of Compound IA-2:

[0180] The compound 3-(4-methylpiperazin-1-yl)-5-hydroxyquinoline (30.0mg, 0.123mmol) was dissolved in THF (1ml), and Cs was added under ice-cooling 2 CO 3 (60.3mg, 0.185mmol), after stirring for 10min, m-fluorobenzyl bromide (25.5mg, 0.136mmol) was added to the reaction solution under nitrogen protection, the temperature was slowly raised to room temperature, stirred for two hours, concentrated and purified by column chromatography The target compound IA-2 (37.9 mg, 0.108 mmol) was obt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a quinoline compound which is used as a c-Met depressant and is expressed by the general formula (I) below, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate and a preparation method of the compound, a medicament combination containing the compound and application of the compounds in the preparation of medicaments for preventing or treating diseases relevant to abnormal cell proliferation, morphological change and hyperkinesia with respect to hepatocyte growth factor receptors (HGFR) in an organism as well as diseases relevant to angiogenesis or cancerometastasis, especially medicaments for treating or preventing growth and metastasis of tumors.

Description

technical field [0001] The present invention relates to a class of quinoline compounds used as c-Met inhibitors and their pharmaceutically acceptable salts or pharmaceutically acceptable solvates, their preparation methods, pharmaceutical compositions containing the compounds, and these compounds In preparation for the prevention or treatment of diseases related to abnormal cell proliferation, morphological changes and hyperkinetic function related to the hepatocyte growth factor receptor (HGFR) in vivo, as well as diseases related to angiogenesis or cancer metastasis Use of medicines, especially medicines for treating or preventing tumor growth and metastasis. Background technique [0002] Hepatocyte growth factor (hepatocyte growth factor, HGF), also known as scatter factor (SF), is the endogenous ligand of c-Met, a family of tyrosine kinase receptors. Proto-oncogene Met and HGF / SF are co-expressed in breast cancer, colon cancer, gastric cancer, prostate cancer and other ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D215/38C07D405/04C07D409/04C07D401/12A61K31/635A61K31/496A61P35/00A61P35/04
CPCA61K31/4709C07D215/38A61K31/496C07D405/04C07D409/04A61P35/00A61P35/04
Inventor 张翱耿美玉王元相艾菁刘振凯
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap